In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods

被引:127
作者
Ernst, EJ
Klepser, ME
Ernst, ME
Messer, SA
Pfaller, MA
机构
[1] Univ Iowa Hosp & Clin, Coll Pharm, Iowa City, IA 52242 USA
[2] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA
关键词
D O I
10.1016/S0732-8893(98)00130-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
MK-0991 has demonstrated activity against a variety of fungal pathogens., we evaluated the MIC endpoint for MK-0991 by reading the endpoint using three methods and comparing these results with minimum fungicidial concentrations and electron micrographs, The concentration that resulted in 80% inhibition of fungal growth compared with control, similar to the endpoint for the azole antifungal agents, provided the most consistent results. Additionally, we investigated the time-kill properties of this agent agonist two isolated each of Candida albicans, Candida glabrata and Candida tropicalis at concentrations ranging from 0.125 x MIC to 16 x MIC. Kill curves were performed using RPMI buffered with morpholine propanesulfonic acid as growth media. Samples were obtained at predetermined time points over 24 h and plated for colony counting. Fungicidal activity was observed with one isolate of C. albicans, two isolates of C. glabrata, and one isolate of C. tropicalis. MK-0991 displayed concentration-dependent activity, which was fungicidal or fungistatic depending on the isolate tested. (C) 1999 Elsevier Science Inc.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 14 条
[1]   Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis [J].
Abruzzo, GK ;
Flattery, AM ;
Gill, CJ ;
Kong, L ;
Smith, JG ;
Pikounis, VB ;
Balkovec, JM ;
Bouffard, AF ;
Dropinski, JF ;
Rosen, H ;
Kropp, H ;
Bartizal, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2333-2338
[2]   In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].
Bartizal, K ;
Gill, CJ ;
Abruzzo, GK ;
Flattery, AM ;
Kong, L ;
Scott, PM ;
Smith, JG ;
Leighton, CE ;
Bouffard, A ;
Dropinski, JF ;
Balkovec, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332
[3]   In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds [J].
DelPoeta, M ;
Schell, WA ;
Perfect, JR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1835-1836
[4]   Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro [J].
Franzot, SP ;
Casadevall, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :331-336
[5]   Treatment of murine disseminated candidiasis with L-743,872 [J].
Graybill, JR ;
Najvar, LK ;
Luther, MF ;
Fothergill, AW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1775-1777
[6]   Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 [J].
Graybill, JR ;
Bocanegra, R ;
Luther, M ;
Fothergill, A ;
Rinaldi, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (09) :1937-1939
[7]   Treatment of histoplasmosis with MK-991 (L-743,872) [J].
Graybill, JR ;
Najvar, LK ;
Montalbo, EM ;
Barchiesi, FJ ;
Luther, MF ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :151-153
[8]   Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872) [J].
Hajdu, R ;
Thompson, R ;
Sundelof, JG ;
Pelak, BA ;
Bouffard, FA ;
Dropinski, JF ;
Kropp, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2339-2344
[9]   Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods [J].
Klepser, ME ;
Ernst, EJ ;
Lewis, RE ;
Ernst, ME ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1207-1212
[10]   Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans [J].
Klepser, ME ;
Wolfe, EJ ;
Jones, RN ;
Nightingale, CH ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1392-1395